Skip to Main content Skip to Navigation
Journal articles

Disrupting the CD95-PLC gamma 1 interaction prevents Th17-driven inflammation

Abstract : CD95L is a transmembrane ligand (m-CD95L) that is cleaved by metalloproteases to release a soluble ligand (s-CD95L). Unlike m-CD95L, interaction between s-CD95L and CD95 fails to recruit caspase-8 and FADD to trigger apoptosis and instead induces a Ca2+ response via docking of PLC gamma 1 to the calcium-inducing domain (CID) within CD95. This signaling pathway induces accumulation of inflammatory Th17 cells in damaged organs of lupus patients, thereby aggravating disease pathology. A large-scale screen revealed that the HIV protease inhibitor ritonavir is a potent disruptor of the CD95-PLC gamma 1 interaction. A structure-activity relationship approach highlighted that ritonavir is a peptidomimetic that shares structural characteristics with CID with respect to docking to PLC gamma 1. Thus, we synthesized CID peptidomimetics abrogating both the CD95-driven Ca2+ response and transmigration of Th17 cells. Injection of ritonavir and the CID peptidomimetic into lupus mice alleviated clinical symptoms, opening a new avenue for the generation of drugs for lupus patients.
Document type :
Journal articles
Complete list of metadata
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Thursday, January 10, 2019 - 1:35:02 PM
Last modification on : Thursday, February 25, 2021 - 1:38:25 PM



Amanda Poissonnier, Jean-Philippe Guegan, Ha Thanh Nguyen, Daniel Best, Nicolas Levoin, et al.. Disrupting the CD95-PLC gamma 1 interaction prevents Th17-driven inflammation. Nature Chemical Biology, Nature Publishing Group, 2018, 14 (12), pp.1079-+. ⟨10.1038/s41589-018-0162-9⟩. ⟨hal-01976911⟩



Record views